GSK-2485852

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H25BF2N2O6S
Molecular Weight	554.37
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=O)C1=C(OC2=C1C=C(C3CC3)C(=C2)N(CC4=CC=C(B(O)O)C(F)=C4)S(C)(=O)=O)C5=CC=C(F)C=C5

InChI

InChIKey=GDSKPIAEYNJODX-UHFFFAOYSA-N

InChI=1S/C27H25BF2N2O6S/c1-31-27(33)25-20-12-19(16-4-5-16)23(13-24(20)38-26(25)17-6-8-18(29)9-7-17)32(39(2,36)37)14-15-3-10-21(28(34)35)22(30)11-15/h3,6-13,16,34-35H,4-5,14H2,1-2H3,(H,31,33)

HIDE SMILES / InChI

Molecular Formula	C27H25BF2N2O6S
Molecular Weight	554.37
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:51:28 GMT 2023` Edited by `admin` on `Sat Dec 16 11:51:28 GMT 2023`
Record UNII	6G04C5ZNQJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GSK-2485852

Common Name

English

GSK-5852

Code

English

B-(4-(((5-CYCLOPROPYL-2-(4-FLUOROPHENYL)-3-((METHYLAMINO)CARBONYL)-6-BENZOFURANYL)(METHYLSULFONYL)AMINO)METHYL)-2-FLUOROPHENYL)BORONIC ACID

Systematic Name

English

BORONIC ACID, B-(4-(((5-CYCLOPROPYL-2-(4-FLUOROPHENYL)-3-((METHYLAMINO)CARBONYL)-6-BENZOFURANYL)(METHYLSULFONYL)AMINO)METHYL)-2-FLUOROPHENYL)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

53354790

Created by admin on Sat Dec 16 11:51:28 GMT 2023 , Edited by admin on Sat Dec 16 11:51:28 GMT 2023

PRIMARY

FDA UNII

6G04C5ZNQJ

Created by admin on Sat Dec 16 11:51:28 GMT 2023 , Edited by admin on Sat Dec 16 11:51:28 GMT 2023

PRIMARY

CAS

1331942-30-3

Created by admin on Sat Dec 16 11:51:28 GMT 2023 , Edited by admin on Sat Dec 16 11:51:28 GMT 2023

PRIMARY

Related Record Type Details


					6G04C5ZNQJ

GSK-2485852

ACTIVE MOIETY

Comments:

GSK2485852 (referred to here as GSK5852) is a hepatitis C virus (HCV) NS5B polymerase inhibitor with 50% effective concentrations (EC50s) in the low nanomolar range in the genotype 1 and 2 subgenomic replicon system as well as the infectious HCV cell culture system. We have characterized the antiviral activity of GSK5852 using chimeric replicon systems with NS5B genes from additional genotypes as well as NS5B sequences from clinical isolates of patients infected with HCV of genotypes 1a and 1b. The inhibitory activity of GSK5852 remained unchanged in these intergenotypic and intragenotypic replicon systems. GSK5852 furthermore displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations P495L, M423T, C316Y, and Y448H. GSK5852 was more potent than HCV-796, an earlier inhibitor in this class, and showed greater reductions in HCV RNA during long-term treatment of replicons. GSK5852 is similar to HCV-796 in its activity against multiple genotypes, but its superior resistance profile suggests that it could be an attractive component of an all-oral regimen for treating HCV.


					6G04C5ZNQJ

GSK-2485852

ACTIVE MOIETY

Comments:

Originator: GlaxoSmithKline; Class: Antiviral; Mechanism of Action: Hepatitis C virus NS 5 protein inhibitor; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: No development reported for Hepatitis C; Most Recent Events: 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(Combination therapy) in USA (IV), 28 Feb 2011 Phase-I clinical trials in Hepatitis C in USA (IV)